General practice pharmacist scheme evaluation indicates ‘improved capacity’ as the main benefit

General practice pharmacist scheme evaluation indicates ‘improved capacity’ as the main benefit

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients...

Asthma deaths levels increase by a quarter in a decade

Asthma deaths levels increase by a quarter in a decade

July 26 2018 There were 1,320 deaths due to asthma in England and Wales in 2017, the highest...

NPA and Age UK ask for help on building polypharmacy dossier

NPA and Age UK ask for help on building polypharmacy dossier

July 25 2018 The National Pharmacy Association is asking its members for case studies on...

Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

July 24 2018 New Health Secretary Matt Hancock has called for investment in primary care and...

NHS Digital seeks views on SCR with Additional Information

NHS Digital seeks views on SCR with Additional Information

July 24 2018 A survey to assess the benefits and/or disadvantages of health professionals...

  • General practice pharmacist scheme evaluation indicates ‘improved capacity’ as the main benefit

    General practice pharmacist scheme evaluation indicates ‘improved capacity’ as the main benefit

    Tuesday, 31 July 2018 15:31
  • Asthma deaths levels increase by a quarter in a decade

    Asthma deaths levels increase by a quarter in a decade

    Thursday, 26 July 2018 15:08
  • NPA and Age UK ask for help on building polypharmacy dossier

    NPA and Age UK ask for help on building polypharmacy dossier

    Wednesday, 25 July 2018 13:46
  • Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

    Pharmacy bodies welcome Health Secretary’s pledge to invest in community pharmacy

    Tuesday, 24 July 2018 12:53
  • NHS Digital seeks views on SCR with Additional Information

    NHS Digital seeks views on SCR with Additional Information

    Tuesday, 24 July 2018 12:41

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

pills1577x362June 10 2014
Applies to tramadol, lisdexamfetamine, zopiclone and zaleplon
Changes to the legal classification of four Controlled Drugs came into effect on June 10, 2014.

The Royal Pharmaceutical Society has summarised the changes, made in The Misuse of Drugs and Misuse of Drugs (Safe Custody) (Amendment) (England, Wales and Scotland) Regulations 2014:

tramadol has become a Schedule 3 controlled drug (CD No Register POM), but will be exempt from safe custody regulations.
lisdexamfetamine becomes a Schedule 2 controlled drug (CD POM)
zopiclone and zaleplon become Schedule 4 part 1 controlled drugs (CD Benz POM).

Both the Society and Community Pharmacy Scotland have published tables summarising the various requirements for storage, supply and prescriptions for the four drugs, and some FAQs.

The changes mean that any prescriptions written and dated before June 10 2014 are now valid for only 28 days, and the maximum quantity supplied should not exceed 30 days.

The RPS points out that tramadol will no longer be able to be prescribed under the NHS repeat dispensing scheme.

However, as Schedule 4 Part 1 drugs can be repeat dispensed, any repeat prescriptions for zopiclone or zaleplon must initially be dispensed within 28 days of the prescription being issued.

In Scotland tramadol, zopiclone and zaleplon cannot be prescribed on CMS serial prescriptions.

Changes to temazepam with regards exemption from schedule 2 and 3 prescription form requirements had been expected in this legislative change, but the RPS says that the Home Office is still reviewing the situation.

As such, for the time being, "temazepam will still be exempt from schedule 2 and 3 prescription form requirements after 10th June 2014."

Links:

Royal Pharmaceutical Society (member only access)

Community Pharmacy Scotland

The Regulations

Practice News

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients and workload changes as the main benefits of the scheme.
July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk of complications compared with staying on metformin, a BMJ study has concluded. However, the study has...